MED
Medifast (MED)
NYSE
$10.66-$0.37 (-3.31%)
Price as of Jun 23, 2026 2:50 PM EDT
  • $122.5M
    Market Cap
  • -17.21%
    1-Year Change
  • Personal Services
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 5
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

What Science-Backed Subscription Health Programs Measure Differently

As the weight loss and diet management market expands toward $45 billion by 2030, marketing terms like 'clinically studied' and 'science-backed' lack standardized definitions, allowing programs to apply them to everything from full randomized controlled trials to single ingredient studies. The article emphasizes that rigorous research should use DXA scanning for body composition measurement rather than scale weight alone, and highlights high study completion rates as indicators of credible outcomes reflecting broad participant experiences.

06/11/2026, 7:00 AM • GlobeNewswire

Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management

Research shows that declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, outcomes that standard weight management programs don't address. A study demonstrates that coach-guided programs achieve up to 10 times more weight loss and 17 times more fat loss compared to self-directed efforts, while retaining 98% of lean mass. Experts emphasize that body composition metrics—visceral fat levels, lean mass retention, and insulin sensitivity—are more meaningful indicators of progress than scale weight alone for midlife women.

06/11/2026, 7:00 AM • GlobeNewswire

The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do

OPTAVIA released research findings showing that clients using their Optimal Weight 5 & 1 Plan with coach support lost up to 10 times more weight and 17 times more fat compared to self-directed participants. The study highlights the importance of human coaching in weight management programs, with research indicating that higher retention rates directly correlate with better weight loss outcomes. OPTAVIA coaches complete a certification program and provide accountability and emotional support rather than clinical guidance.

05/21/2026, 7:00 AM • GlobeNewswire

Peer-Reviewed Research Is Redefining Weight Loss Program Standards

OPTAVIA, backed by 18 randomized controlled trials and 100+ peer-reviewed publications, demonstrates that its structured meal replacement program reduces visceral fat by 14% and preserves 98% of lean mass over 16 weeks. Research shows clients working with coaches lose 10 times more weight and 17 times more fat compared to those without coaching support, highlighting the importance of human accountability in weight loss programs.

05/15/2026, 1:00 PM • GlobeNewswire

Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation

Clinical research demonstrates that structured meal replacement programs produce superior body composition outcomes compared to self-directed weight loss approaches. OPTAVIA's Optimal Weight 5 & 1 Plan achieved 14% visceral fat reduction while preserving 98% of lean mass over 16 weeks. Coach-guided programs showed participants lost up to 10 times more weight and 17 times more fat than those attempting weight loss independently, highlighting the importance of accountability in sustained behavior change.

05/15/2026, 1:00 PM • GlobeNewswire

The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings

The global consumer healthcare market is experiencing a structural shift where regulatory compliance and FDA approval have become critical competitive advantages. Major companies including Philip Morris, Celsius Holdings, USANA Health Sciences, and Medifast are advancing strategic initiatives focused on regulatory readiness, product integration, and market expansion. Doseology Sciences has partnered with McKinney Regulatory Science Advisors to strengthen its FDA pathway for oral pouch products.

01/19/2026, 12:10 PM • Benzinga

Weight Management Market Outlook to 2030: 7.6% CAGR as Digital Adoption Rises and Preventive Health Focus Strengthens, Says Mordor Intelligence

The global weight management market is valued at USD 39.07 billion in 2025 and is projected to reach USD 60.48 billion by 2030, growing at a 7.6% CAGR. Growth is driven by rising obesity prevalence, digital platform adoption, and a shift toward holistic, sustainable weight management programs. North America leads the market while Asia-Pacific is the fastest-growing region.

12/24/2025, 5:05 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$10.94
$11.57
$11.02
1-Year Range
$9.53
$15.22
$11.02
Latest Close$11.02
Change
-$0.02 (-0.18%)
Volume344,998
Market Cap$122.5M
Shares Outstanding11.1M
P/E (TTM)-6.05
Diluted EPS (TTM)-$1.82
Enterprise Value$51.0M

Information as of 06/22/2026

Company Profile

$122.5M
Market Cap
-$20.0M
Net Income
Sector: Consumer Cyclical
Industry: Personal Services
1501 S. Clinton Street, Baltimore, MD, United States, 21224
410 581 8042

Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address weight loss in the United States. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, essential amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements. It also provides lifestyle plans consisting of 5 & 1 Plan and 5 & 1 ACTIVE Plan, which provides a targeted reset of the body's metabolism by activating strong and targeted fat burn; Optimal Weight 4 & 2 & 1 Plan and Optimal Weight 4 & 2 ACTIVE Plan, which is designed for clients who want to continue eating all food groups or want a flexible meal plan to achieve a healthy weight; OPTAVIA Optimization Plan, a personalized approach to help clients' long-term weight management; and OPTAVIA GLP-1 Nutrition Support Plan, a nutritional companion to GLP-1 medication that allows clients to focus on weight loss without the stress of figuring out what to eat. In addition, the company offers metabolic synchronization, a science that reverses metabolic dysfunction through a targeted reset of the body's metabolism. It markets its products through point-of-sale transactions executed over an e-commerce platform. The company serves health and wellness consumers. The company was formerly known as Healthrite, Inc. and changed its name to Medifast, Inc. in May 2001. Medifast, Inc. was incorporated in 1980 and is headquartered in Baltimore, Maryland.

Key Executives

  • Daniel R. Chard
  • James Maloney
  • Nicholas Johnson
  • Jason L. Groves
  • Jonathan Barrett MacKenzie

Current Ownership Distribution

  • Mutual Funds1.1B (85.69%)
  • Institutions177.8M (13.79%)
  • Insiders6.7M (0.52%)
  • Other0 (0.00%)